🇺🇸 FDA
Patent

US 11186566

Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

granted A61PA61P1/16A61P1/18

Quick answer

US patent 11186566 (Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P1/16, A61P1/18, A61P11/00, A61P11/12